Please type a plus sign (+) inside this box → +
Approved for use through 10/31/99 OMB 0651-00

Examiner

Signature

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF MARKETS AND TRADES AND TR

Under the Paperwork Reduction Act of 1995, no persons are required collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/073,301 Filing Date INFORMATION DISCLOSURE 02/13/2002 First Named Inventor Reiter STATEMENT BY APPLICANT Group Art Unit 1641 (use as many sheets as necessary) **Examiner Name** M. DiBrino Sheet Of Attorney Docket Number 01/23094 **U.S. PATENT DOCUMENTS** U.S. Patent Document Pages, columns, lines, Where Re Kind Code<sup>2</sup> Examiners In Cite No. Number Date of Publication of Cited Passages or Relevant Figures Appe Name of Patentee or Applicant (if known) Document MM-DD-YYYY of Cited Document 3,901,654 Gross 08-26-1975 3,879,262 Schuurs et al 04-22-1975 3,853,987 Dreyer 12-10-1974 3,867,517 Ling 02-18-1975 3,850,752 Schuurs et al 11-26-1974 3,850,578 McConnell 11-26-1974 3,839,153 Schuurs et al 10-01-1974 3,791,932 Schuurs et al 02-12-1974 FOREIGN PATENT DOCUMENTS Foreign Patent Documents Examiners In Cite N Name of Patentee or Date of Publication of Cited Pages, columns, lines, Where Office<sup>3</sup> Number<sup>4</sup> Kind Code<sup>5</sup> Applicant of Cited Document Document MM-DD-YYYY Relevant Passages or Relevant known) Figures Appear WO 97/02342 Andersen et al 01-23-1997

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box  $\rightarrow \boxtimes$ Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT Of COMMERCE 1

Tatelli and Trademark Office: U.S. DEPARIMENT Of COMMERCE 5.3

Under	he Paperw	ork Reduction Act of 1995, no persons are required to secure to a collecti		OMB control number. te if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<del></del>	
			Application Number	10/073,301	
			Filing Date	02/13/2002	
			First Named Inventor	Reiter	
			Group Art Unit	1641	
		(use as many sheets as necessary)	Examiner Name	M. DiBaro	
Sheet	1	Of 2	Attorney Docket Number		
		OTHER PRIOR ART – NON PATE	ENT LITERATURE DOCUME	INTS	
Examiner	Cite				
Initials	No.1				
	1	where published.  Andersen et al, "A recombinant antibody with the antigen-specific, major histocompatibility			
$\mathcal{M}\mathcal{I}\mathcal{I}$		complex-restricted specificity of T cells", Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1820-4.			
		Chames et al, 'Direct selection of a human antibody fragment directed against the tumor T-cell			
ΛΛ.		epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library",			
m m	1	Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7969-74.			
NO	:	Reiter et al, "Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin			
		fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cel			
		receptor-like specificity", Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4631-6.			
MO		Cohen, et al, "Direct detection and quantitation of a distinct T-cell epitope derived from			
		tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with			
		the antigen-specific, major histocompatibility complex-restricted specificity of T cells",			
		Cancer Res. 2002 Oct 15;62(20):5835-44.			
	<b></b>				
Examiner			Date		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1.</sup> Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.